Katherine Moldave, MBA
Vice President – Market Support
Katherine Moldave is the co-founder of AlcheraBio and serves as vice president – market support. She has extensive experience in business and strategic planning, marketing planning and strategy, technical communications, product management, and marketing communications in animal health, crop science, and technology.
Ms. Moldave is responsible for overseeing post-marketing studies, as well as special projects. She is also involved in the company’s business development. Ms. Moldave co-authored Clinical Effectiveness and Safety of a New NSAID, Firocoxib: A 1,000 Dog Study, published in July 2006 in Veterinary Therapeutics. The paper is a report on a standard-setting post-marketing study AlcheraBio managed for a major animal health company. Ms. Moldave is also a co-author of a second publication related to that particular study, Switching NSAIDs in practice: insights from the Previcox (firocoxib) Experience Trial, published in Vet Ther. 2007, Winter,8(4):263-7. She is also a coauthor of Field Comparison of Canine NSAIDs Firocoxib and Deracoxib, published in International Journal of Applied Research in Veterinary Medicine, Vol. 8 No. 2, 2010, p. 114-123. Ms. Moldave has contributed to AnimalPharm newsletter and developed strategic white paper that has served as the impetus for the ongoing evolution of the Alliance for Contraception in Cats and Dogs. She serves on ACC&D’s science advisory committee and several ACC&D subcommittees.
Ms. Moldave graduated from Washington University in St. Louis and received her MBA from Fairleigh Dickinson University in New Jersey. Her experience includes 7 years at Merck and Merial in the global marketing and strategic planning organization, and she successfully developed a previous communications business. She has a valuable ability to translate science to non-scientists that helps to bring project teams together and balances science and marketing.